The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

Highlights in myasthenia gravis from AAN 2025 include trials of new therapy inebilizumab, new data on the approved ...

On Wednesday, the U.S. Food and Drug Administration (FDA) granted approval for IMAAVY™ (nipocalimab-aahu), Johnson & ...

The US Food and Drug Administration (FDA) has approved nipocalimab (Imaavy) injection for the treatment of adults and ...

Dr Nicholas Silvestri reflects on promising new and existing treatment options, reinforcing a personalized approach and ...

The FDA has approved a monoclonal antibody to treat individuals aged 12 years and older with generalized myasthenia gravis ...

Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important ... session at the upcoming American Academy of Neurology Annual Meeting. Rozanolixizumab is a high ...

The FDA has approved a monoclonal antibody to treat individuals aged 12 years and older with generalized myasthenia gravis who are ... at the American Academy of Neurology Annual Meeting.

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

Long-term safety and efficacy of nipocalimab in generalized myasthenia gravis: Vivacity-MG3 open-label extension phase results. Neurology. 2025;104(7 suppl 1):P7-11.022. doi:10.1212/WNL.